Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy. METHODS: A case note review of 1122 patients with 1188 episodes of HIV-associated PCP from three observational cohorts in Copenhagen, London and Milan, between 1989 and 2004, was conducted. RESULTS: Trimethoprim/sulfamethoxazole (962 PCP episodes, 81%) was the most frequently used first-line therapy, followed by intravenous pentamidine (87 episodes, 7%), clindamycin/primaquine (72 episodes, 6%) and 'other' (atovaquone, dapsone/pyrimethamine, trimetrexate or inhaled pentamidine; 67 episodes, 6%). Rates of unchanged therapy were trimethoprim/sulfamethoxazole = 79%, clindamycin/primaquine = 65% and pentamidine = 60% (P < 0.001). First-line therapy was changed because of failure in 82 (7%) episodes and because of toxicity in 198 (17%) episodes. Three month survival rates were trimethoprim/sulfamethoxazole = 85%, clindamycin/primaquine = 81% and pentamidine = 76% (P = 0.09). After adjustment for possible confounders, pentamidine was associated with a significantly greater risk of death at 3 months [hazard ratio (HR) = 2.0, 95% confidence interval (CI) = 1.2-3.4]. Second-line therapy survival rates differed: trimethoprim/sulfamethoxazole = 85%; clindamycin/primaquine = 87%; and pentamidine = 60% (P = 0.01). Multivariable time-updated Cox regression analysis showed a greater risk of death associated with pentamidine (HR = 3.3, 95% CI = 2.2-5.0), but not for clindamycin/primaquine, when both were compared with trimethoprim/sulfamethoxazole. CONCLUSIONS: Pentamidine was associated with a greater risk of death when used as first- and second-line therapy for HIV-associated PCP, and was associated with more treatment changes. Clindamycin/primaquine appeared superior to pentamidine as second-line therapy for PCP in patients failing or developing toxicity with trimethoprim/sulfamethoxazole. In patients failing first-line treatment with non-trimethoprim/sulfamethoxazole regimens, second-line therapy should be trimethoprim/sulfamethoxazole.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helweg-Larsen, J., Benfield, T. L., Eugen-Olsen, J., Lundgren, J. D., & Lundgren, B. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03320-6 · Cited by 274 · cited 1×
“jirovecii may limit the efficacy of trimethoprim/sulfamethoxazole, we observed consistent efficacy of first-line treatment with trimethoprim/sulfamethoxazole over time.(24,25) We found equivalent efficacy from trimethoprim/ sulfamethoxazole and clindamycin/primaquine when used for 0.”
ResultSelf-citation
Cited by
Colonization by Pneumocystis jirovecii and Its Role in Disease
Morris, A., & Norris, K. A. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-12 · Cited by 429
A neglected epidemic: Fungal infections in HIV/AIDS
Armstrong-James, D., Meintjes, G., & Brown, G. D. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.01.001 · Cited by 325
Cooley, L., Dendle, C., Wolf, J., Teh, B. W., Chen, S. C., Boutlis, C., & Thursky, K. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12599 · Cited by 228
HIV-Associated Pneumocystis Pneumonia
Huang, L., Cattamanchi, A., Davis, J. L., Boon, S. D., Kovacs, J., Meshnick, S., Miller, R. F., Walzer, P. D., Worodria, W., & Masur, H. (2011) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201009-062wr · Cited by 191
Self-citationTasaka, S., & Tokuda, H. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0453-0 · Cited by 123
Metadata
- Authors
- Helweg-Larsen, J., Benfield, T., Atzori, C., & Miller, R. F.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10-26
- Volume
- 64
- Issue
- 6
- Pages
- 1282-1290
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2136812515
- Cited by
- 102
- References
- 1
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. https://app.cochat.ai/papers/10.1093/jac/dkp372
- The paper
- Helweg-Larsen, J., Benfield, T., Atzori, C., & Miller, R. F. (2009). Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkp372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.